B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a major breakthrough in the treatment of relapsed/refractory (RR) multiple myeloma (MM), offering a high response rate even in high-risk patients [1,2,3,4,5,6]. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.